The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2020 | FLAMSA-reduced intensity vs myeloablative conditioning for R/R AML with disease at transplantation
Eduardo Rodríguez-Arbolí, MD, MPhil, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University of Seville, Seville, Spain, discusses FLAMSA-based reduced-intensity conditioning versus myeloablative conditioning in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with active disease at transplantation. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
